share_log

Blueprint Medicines | 8-K: Blueprint Medicines Reports Strong First Quarter 2024 Results and Raises AYVAKIT ® / AYVAKYT ® (avapritinib) Full Year Revenue Guidance

Blueprint Medicines | 8-K: Blueprint Medicines Reports Strong First Quarter 2024 Results and Raises AYVAKIT ® / AYVAKYT ® (avapritinib) Full Year Revenue Guidance

Blueprint Medicines | 8-K:Blueprint Medicinib 公佈了強勁的2024年第一季度業績,並上調了AYVAKIT® /AYVAKYT®(avapritinib)全年收入指引
美股SEC公告 ·  05/02 07:13
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息